Citizens Jmp Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $34.00

Sutro Biopharma (NASDAQ:STRO) had its price target lowered by Citizens Jmp from $41.00 to $34.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

STRO has been the topic of a number of other research reports. Mizuho set a $50.00 price target on shares of Sutro Biopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Wednesday, August 5th. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a research note on Friday, May 1st. HC Wainwright boosted their target price on shares of Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Stifel Nicolaus set a $48.00 price target on shares of Sutro Biopharma and gave the company a “buy” rating in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sutro Biopharma has a consensus rating of “Buy” and a consensus price target of $47.30.

Sutro Biopharma Price Performance

Sutro Biopharma stock opened at $20.48 on Thursday. The stock’s 50 day moving average is $26.86 and its 200 day moving average is $25.95. The firm has a market cap of $339.56 million, a P/E ratio of -1.86 and a beta of 1.55. Sutro Biopharma has a one year low of $7.15 and a one year high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The company had revenue of $9.84 million during the quarter, compared to analyst estimates of $11.96 million. Equities analysts anticipate that Sutro Biopharma will post -8.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sutro Biopharma

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Sutro Biopharma by 1,052.8% during the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Sutro Biopharma during the 1st quarter worth approximately $19,956,000. Perceptive Advisors LLC acquired a new stake in shares of Sutro Biopharma during the 1st quarter worth approximately $17,818,000. Jane Street Group LLC bought a new stake in shares of Sutro Biopharma in the 2nd quarter valued at $492,000. Finally, ADAR1 Capital Management LLC increased its stake in shares of Sutro Biopharma by 681.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock valued at $13,064,000 after acquiring an additional 457,364 shares in the last quarter. 96.99% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, implying substantial upside from recent levels. The firm raised its EPS forecasts for fiscal 2027 through 2030, including improving estimates for fiscal 2028, 2029 and 2030. HC Wainwright analyst estimates
• Positive Sentiment: Wedbush reaffirmed its Outperform rating and $60 price target, while Citizens JMP retained a Market Outperform rating despite reducing its target to $34. These targets indicate analysts still see meaningful potential if Sutro’s pipeline and commercial prospects develop as expected. Analyst rating updates
• Neutral Sentiment: A market roundup described analysts as having conflicting views on Sutro and other healthcare companies, highlighting a divergence between optimistic ratings and concerns about ongoing losses and execution risk. Analysts have conflicting sentiments on healthcare companies
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates to losses of $2.38 and $2.46, respectively, from $2.32 previously for both periods. Although later-year estimates improved, the revisions reinforce expectations for continued heavy cash burn and losses.
• Negative Sentiment: Sutro’s latest quarterly results missed expectations: adjusted loss per share was $2.33 versus the consensus loss estimate of $2.19, while revenue of $9.84 million fell short of the $11.96 million forecast. The disappointing results likely contributed to the selling pressure and elevated trading volume.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.